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Introduction
The response of cells to environmental signals, as well as their
differentiation, death or malignant transformation, involves
changes in gene expression. For many years, the modulation
of gene expression was thought to be restricted to, or at least
dominated by, the control of transcription. According to the
Jacob-Monod-Lwoff paradigm, established in bacteria and
logically extended to eukaryotes, what made a cell a cell was
the combinatorial turning on and off of genes. The discovery
of introns and the process of splicing, which eliminates them
from the precursor mRNA, introduced an exciting but also
perturbing factor in our simplified conceptions of the flow of
gene expression in eukaryotes. Introns must be excised
precisely to generate bona fide mRNA molecules; otherwise,
translational frame shifts would be introduced. Introns are
much longer than exons and most of their nucleotide sequence
seems to be irrelevant except for the ‘donor’ and ‘acceptor’
consensus sequences located at their extremities, and the
branching sequence that precedes the acceptor sequence. The
spliceosome, a sophisticated nuclear machine comprising five
types of small nuclear ribonucleoprotein (snRNP) and
hundreds of auxiliary proteins, takes care of intron excision and
exon joining repeatedly at each and every one of the seven
splicing events that occur on average per human pre-mRNA
molecule (Lander et al., 2001).
‘What is all this for?’, a teleologist might ask. We know now
that the high adaptive value of introns resides in the fact that
they permitted exon shuffling in the past and alternative
splicing in the present (Sharp, 1994). However, the apparent
‘irrationality of introns’ (I. Eperon, http://www.eurasnet.info/
ian_eperon.shtml) was questioned early on following the
discovery that mutations that affect splicing, quantitatively or
qualitatively, are a widespread source of hereditary diseases.
No matter how absurd or energy consuming a biological
process appears to be, if its disruption or perturbation causes
disease, it must be important, and its conservation in evolution
is paramount. The links between splicing and human disease
have been extensively reviewed lately (Caceres and Kornblihtt,
2002; Cartegni et al., 2002; Faustino and Cooper, 2003; Pagani
and Baralle, 2004). The specific association between splicing
and cancer has received less attention (Brinkman, 2004;
Venables, 2006), perhaps because the field is still emerging.
Here we examine this connection, focusing not only on
mutations in cis-acting splicing sequences that are associated
with cancer but also on the variations in normal splicing
processes and the signals that may affect them in cancer cells.
The basic language of splicing
Splice sites, branch sites, splicing enhancers and
splicing silencers
Splicing occurs when a group of proteins and RNPs recognize
specific RNA sequences conserved at the boundaries of introns
(Fig. 1A). The classical spliceosome, which acts on >99% of
introns from genes transcribed by RNA polymerase II (Pol II),
recognizes a 5 donor splice site beginning with a GU
dinucleotide and a 3 acceptor splice site ending with an AG
dinucleotide (the GU-AG rule). A second type of spliceosome
acts on a minor class of Pol-II-transcribed introns obeying the
AU-AC rule (Tarn and Steitz, 1996). In the major class of
introns, the 5 splice site, the branch site in between and the 3
splice site are recognized by U1 snRNP, U2 snRNP and the
auxiliary factor U2AF, respectively. The splicing reaction is
completed with the participation of the U4, U6 and U5 snRNPs
(Sharp, 1994). Every internal exon is flanked by upstream and
downstream splice sites. The situation is different for the
terminal exons: the upstream limit of the first exon is the Cap
site or transcription initiation site, whereas the downstream
limit of the last exon is the polyadenylation site (Fig. 1B).
These particular features are important considerations for
alternative splicing (see below).
When the sequence of a splice site deviates from the
consensus shown in Fig. 1A, the site can still be used, although
less efficiently, depending on the number of base changes.
These weak sites (Fig. 1C) have less affinity for their
spliceosomal protein or RNP partners and are the main cause
of alternative splicing. A second class of cis-acting sequence
Alternative splicing is a crucial mechanism for generating
protein diversity. Different splice variants of a given protein
can display different and even antagonistic biological
functions. Therefore, appropriate control of their synthesis
is required to assure the complex orchestration of cellular
processes within multicellular organisms. Mutations in cis-
acting splicing elements or changes in the activity of
regulatory proteins that compromise the accuracy of either
constitutive or alternative splicing could have a profound
impact on human pathogenesis, in particular in tumor
development and progression. Mutations in splicing
elements, for example, have been found in genes such as
LKB1, KIT, CDH17, KLF6 and BRCA1, and changes in
trans-acting regulators can affect the expression of genes
such as Ron, RAC1 and CD44.
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can influence the recognition and use of weak sites by the
splicing apparatus: the enhancers and silencers of splicing.
These are short (~10 nucleotides) conserved sequences located
in exons or introns, either isolated or in clusters, that stimulate
or inhibit the use of weak splice sites (Fig. 1D). An exonic
sequence is defined as an exonic splicing enhancer (ESE) if its
mutation reduces inclusion of the corresponding exon into the
mature mRNA. Conversely, mutation of an exonic splicing
silencer (ESS) increases inclusion of the exon. In most cases,
the mechanisms of action of splicing enhancers and silencers
involve the specific binding of regulatory proteins such as
SR proteins (serine/arginine-rich proteins) or heterogeneous
nuclear (hn)RNPs (Dreyfuss et al., 1993; Graveley, 2000;
Manley and Tacke, 1996). Certain silencers, instead of binding
regulatory proteins, form a particular pre-mRNA secondary
structure that hinders the recognition of a neighboring splicing
enhancer by SR proteins (Buratti et al., 2004).
Approximately 15% of mutations that cause genetic disease
affect pre-mRNA splicing. Some disrupt or create splice sites.
If a canonical splice site is completely disrupted, a cryptic
splice site nearby is used instead, leading to aberrantly spliced
mRNA molecules and failure to produce a functional protein.
If the disruption is partial, the cryptic and mutated sites
compete, leading to a mixed population of aberrant and normal
mRNA molecules, with a reduction in normal protein levels.
Creation of a new splice site has similar consequences: the new
(aberrant) and the old site compete and there is a concomitant
reduction in normal protein levels.
Recently, the role of mutations that create or abolish splicing
enhancers and silencers in disease has been examined
(Cartegni et al., 2002; Pagani and Baralle, 2004). This is
particularly important when one studies single base changes in
exonic sequences. Traditionally, these base changes were
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assumed to produce nonsense, missense or silent substitutions
that could only affect the quality of the encoded protein.
However, we now know that in many cases they disrupt or
create functional ESEs or ESSs, and provoke changes in the
levels of inclusion of the exons to which they map. 
Alternative splicing
When two or more splice sites compete, alternative splicing
generates mRNA variants that yield different polypeptides
from a single gene (reviewed by Black, 2003). Alternative
splicing is more a rule than an exception: it affects an estimated
60% of human genes (Lander et al., 2001). Its regulation not
only depends on the interaction of SR and hnRNP proteins with
splicing enhancers and silencers, but is also coupled to Pol II
transcription, as in the case of other pre-mRNA processing
reactions (reviewed by Bentley, 2005; Kornblihtt et al., 2004;
Maniatis and Reed, 2002; Proudfoot et al., 2002).
Fig. 2A illustrates the different modes of alternative splicing,
which we distinguish from alternative transcriptional initiation
(Fig. 2B). Alternative transcriptional initiation generates
mRNA diversity but is not alternative splicing because there
are no competing splice sites.
Cancer and mutations that affect splicing
Many examples of cancer-associated alterations in splicing are
attributable to mutations that create or disrupt splice sites or
splicing enhancers and silencers. However, in only a few cases
has a cause-effect relationship been proved. Below we discuss
some recent examples, which are summarized in Table 1.
LKB1
LKB1 is a tumor suppressor gene that encodes a serine/
threonine protein kinase involved in the control of several
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Fig. 1. Cis-acting sequences that control
splicing. (A) Consensus sequences for the
5 splice site (donor), branch site and 3
splice site (acceptor). (B) Arrangement of
donor (D) and acceptor (A) sites in the
architecture of a typical eukaryotic gene.
Whereas internal exons are limited by
acceptor and donor sites, the first exon is
limited by the Cap site and a donor, and
the last exon is limited by an acceptor and
the poly(A) site. (C) Examples of
sequences for strong and weak acceptor
sites. Red indicates the 3 acceptor splice
site; bold indicates deviations from the
consensus sequence. (D) Schematic roles
of exonic splicing enhancers (ESE),
exonic splicing silencers (ESS), intronic
splicing enhancers (ISE) and intronic
splicing silencers (ISS) on the recognition
of a weak acceptor by the splicing
machinery; red indicates enhancing, blue













cellular processes, including cell-cycle arrest, p53-mediated
apoptosis, Ras-induced transformation, cell polarity. Its second
intron belongs to the minor spliceosome class that obeys the
AU-AC rule. Mutations of LKB1 that lead to reduced levels of
the protein are found in patients with Peutz-Jeghers Syndrome
(PJS), an autosomal dominant disorder associated with
gastrointestinal polyposis and an increased cancer risk. A
group of PJS patients carry a mutation that affects the 5 splice
site of intron 2 (IVS2+1A>G). Interestingly, the mutated 5
splice site is still used but not in conjunction with its normal
3 splice site. Instead, cryptic, non-canonical 3 splice sites
adjacent to the normal one are used, which leads to
frameshifting and consequently to the appearance of premature
termination codons in the aberrantly spliced transcripts
(Hastings et al., 2005). The mutation thus affects the fidelity
of splicing. It also provides a tool to dissect the differences
between minor and major spliceosome requirements.
KIT
Another interesting example involves the oncogene KIT. The
encoded protein is a member of the type III receptor tyrosine
kinase family whose constitutive activation is associated with
gastrointestinal stromal tumors. Chen et al. found patients with
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Fig. 2. (A) Different modes of
alternative splicing. (B) Alternative
promoters provoke mRNA diversity but
do not necessarily imply alternative
splicing. There are two alternative
promoters, P1 and P2. If promoter P2 is
used, exons 2, 3 and 4 are constitutively
included. If promoter P1 is used, exon 2
simply does not exist for the splicing
machinery because, being a 5 terminal
exon of the P1 transcription unit, it lacks
an upstream 3 splice site. Therefore,
the splicing machinery has no option but
to join exon 1 directly to exon 3,
generating a 1-3-4 mRNA.
Table 1. Examples of mutations in splicing cis-acting sequences that are associated with malignant disease
Gene (function) Disease Mutated sequence Molecular consequences Ref.
LKB1 Peutz-Jeghers Syndrome IVS2+1A>G Disruption of minor spliceosome; mutated 5 Hasting et al., 2005
(tumor suppressor) (increased cancer risk) splice site is still used, together with cryptic, non-
canonical 3 splice sites; lower protein levels
KIT Gastrointestinal stromal Deletion of 30 or 34 Aberrant splicing; constitutive protein activation Chen et al., 2005
(oncogene) tumor nucleotides including 
IVS10 3 splice site 
CDH17 Hepatocellular carcinoma IVS6+35A>G Generation of an ISS(?); exon 7 skipping Wang et al., 2005
(LI-cadherin)
CDH17 Hepatocellular carcinoma E6 codon 651 Generation of a ESS(?); exon 7 skipping Wang et al., 2005
(LI-cadherin)
KLF6 Prostate cancer IVS1-27G>A Generation of binding site (ISE) for SRp40; novel Narla et al., 2005
(tumor suppressor) (‘IVSA allele’) splicing variants act as dominant negatives
HAS1 Multiple myeloma E3 C7760T Exon 4 skipping Adamia et al., 2005
(hyaluronan synthase)













site of intron 10; these deletions concomitantly create an intra-
exonic 3 splice site within exon 11 (Chen et al., 2005). The
resulting polypeptides remain in-frame but lack an internal
stretch that is crucial for auto-inhibition of the kinase.
Structural studies of the mutated kinase revealed a
conformation consistent with constitutive activation.
CDH17
Liver intestine cadherin (LI-cadherin) is a cell-cell adhesion
protein present in the plasma membrane. Its gene, CDH17,
has been reported to be overexpressed in hepatocellular
carcinomas, as well as in gastric and pancreatic cancer.
Similarly, splicing variants lacking exon 7 are strongly
associated with poor prognosis and a high incidence of tumor
recurrence. Exon 7 skipping seems to be caused by two types
of point mutation: disruption of the branch site of intron 6 and
a base change at position 651 of exon 6 (Wang et al., 2005).
The latter might affect exon 7 inclusion by generating an ESS
or disrupting an ESE located in exon 6. Why the lack of the
protein segment encoded by exon 7 provokes effects similar to
those resulting from overexpression of the full-length CDH17
remains to be determined.
KLF6
A case in which the molecular defect is better defined is a point
mutation in intron 1 of the KLF6 gene that generates a binding
site for the SR protein SRp40. KLF6 is a Kruppel-like Zn-
finger transcription factor that functions as a tumor suppressor
and is somatically inactivated in prostate cancer (Narla et al.,
2005). The new site for SRp40 apparently works as an atypical
intronic splicing enhancer (ISE), provoking the use of three
cryptic splice sites in exon 2. The proteins predicted to arise
from the aberrant mRNAs lack parts of the activation and/or
DNA-binding domain and presumably act as dominant-
negative mutants.
BRCA1
Germline mutations in the BRCA1 gene are well-known
markers of predisposition to breast and ovarian cancers. An
inherited point mutation in exon 18, classifiable as a nonsense
mutation, was the first shown to affect splicing: it disrupts an
ESE and provokes exon 18 skipping (Mazoyer et al., 1998).
Since then, a panoply of mutations that presumably affect
splicing enhancers and silencers have been described in
BRCA1. A recent in silico approach using the program
ESEfinder (Cartegni et al., 2003) identified 23 highly
conserved ESEs in the 22 exons of the BRCA1 gene. About
60% of these ESEs are predicted to be affected by sequence
variants reported in the Breast Cancer Information Core
(Pettigrew et al., 2005). These findings stress how crucial it is
when one attempts to interpret the molecular basis of genetic
disease to define whether base changes in coding regions act
at the translational level (generating amino acid changes, stop
codons, or silent mutations) or affect splicing.
Cancer-associated alterations of splicing patterns
The splicing patterns of several genes have been reported to be
altered in cancers, including those encoding the prolactin
receptor, Ron, Rac1, fibronectin, fibroblast growth factor
receptor, CD44, MDM2 and IIp45. The fact that no mutations
have been observed in cis-acting splicing elements within these
genes suggests that the alterations could be due to changes
in trans-acting splicing regulators. Furthermore, certain
alternatively spliced isoforms of proteins such as Ron and Rac1
can accumulate in tumors, and overexpression of the tumor-
associated isoforms is sufficient to transform cells in culture
(Singh et al., 2004; Zhou et al., 2003). Below, we discuss a few
examples that affect cell growth, adhesion, migration, invasion
and apoptosis, as well as the connection between signaling
pathways and splicing regulation.
Ron
Ron is a heterodimeric protein formed by  and  subunits,
both derived from the proteolytic cleavage of a common
precursor. It is the tyrosine kinase receptor for macrophage-
stimulating protein, and binding to this ligand triggers a
signaling cascade that regulates a variety of cellular activities,
such as cell growth, motility and invasion of extracellular
matrices. These occur during epithelial-to-mesenchymal
transition (EMT), a process that is essential for embryonic
development and also participates in tumor progression in
epithelial tissues (Radisky, 2005; Thiery and Sleeman, 2006).
An alternatively spliced isoform termed Ron was identified
in human gastric carcinoma cells and induces an invasive
phenotype in transfected cells (Collesi et al., 1996). Ron
mRNA originates by skipping of exon 11, which leads to the
deletion of a 49 amino acid stretch in the  chain of the
resulting polypeptide. This deletion abolishes the proteolytical
cleavage and renders the protein constitutively active.
Ghigna et al. not only confirmed that Ron splicing is altered
in breast and colon cancers but also shed light on the molecular
mechanism that regulates it (Ghigna et al., 2005). They
identified two regulatory elements within exon 12 that control
the level of inclusion of exon 11. The binding of the SR protein
SF2/ASF to one of these stimulates skipping of exon 11,
increasing the level of the Ron isoform. More excitingly, not
only does overexpression of SF2/ASF lead to morphological
and molecular changes characteristic of an EMT, but
knockdown of SF2/ASF by RNA interference (RNAi) reduces
the levels of Ron and concomitantly decreases cell motility.
Similarly, RNAi directed against Ron reduces cell motility
and partially reverses the morphological changes induced by
overexpression of SF2/ASF. Thus, SF2/ASF could regulate
malignant transformation of certain epithelial tumors by
inducing a Ron-dependent EMT.
Other trans-acting regulators could act in the same way and
we can therefore speculate that variations in expression and/or
activity of splicing factors could lead to changes in the splicing
patterns of certain mRNAs whose protein products are involved
in different stages of tumor progression. The obvious question
is which signaling molecules control SR protein activity and
what events lead to their deregulation.
Rac
Matrix metalloproteases (MMPs) are upregulated in nearly all
cancers (Egeblad and Werb, 2002). Their activity modifies
cell-cell and cell-substratum adhesion, promoting tumor
cell proliferation, invasion, angiogenesis and metastasis. In
addition, they influence genomic surveillance, causing
genomic instability (Radisky and Bissell, 2006). MMPs have
also been implicated in splicing regulation. Radisky et al.
demonstrated that synthesis of Rac1b, an alternatively spliced












isoform of the Rho-family GTPase Rac1, is induced by
treatment of normal mammary epithelial cells with MMP-3 and
that Rac1b activity is required for MMP-3-triggered EMT in
these cells (Radisky et al., 2005).
Rac1b is generated by inclusion of a 57-nucleotide cassette
exon. It accumulates in colorectal and breast tumors, and shows
transforming properties when overexpressed in cultured cells.
Unlike the Ron example, the factors that regulate RAC1
splicing have not yet been characterized. However, preliminary
evidence indicates that changes in SR protein expression
modulate RAC1 splicing patterns (F. Pelisch, D. Radisky and
A.S., unpublished results). Moreover, MMP-3-dependent
Rac1b synthesis triggers an increase in cellular reactive oxygen
species (ROS), leading to genomic instability (Radisky et al.,
2005), which can drive tumorigenesis. Li and Manley have
linked genomic instability to SR protein function (Li and
Manley, 2005). They showed that, when cultured cells are
depleted of SF2/ASF, nascent pre-mRNA remains hybridized
to the template DNA strand, leading to increased damage to
the displaced complementary DNA strand. They propose that
coupling between transcription and pre-mRNA processing
therefore not only assures efficient production of mature
mRNAs but also protects chromosomes from potentially
deleterious DNA damage. Further investigations will reveal
whether the expression and/or activity of certain splicing
factors is involved in the genomic instability observed upon
Rac1b production.
p53
The delicate balance between cell proliferation, differentiation
and death maintains tissue homeostasis within multicellular
organisms. Deregulation of any of these processes can lead to
tumorigenesis. Inactivation of the p53 tumor suppressor gene
is a very frequent event in human cancer (Oren, 2003). p53 is
a crucial protein involved in cell-cycle control, apoptosis and
maintenance of genetic stability. It was thought to exist as a
single isoform. However, multiple isoforms generated through
the use of two different promoters and alternative splicing have
recently been discovered, making p53 similar to its relatives
p63 and p73 (Bourdon et al., 2005; Prives and Manfredi, 2005;
Rohaly et al., 2005). Bourdon et al. showed that these isoforms
are expressed in a tissue-dependent manner and that their
expression pattern is altered in human breast tumors (Bourdon
et al., 2005). The regulators of promoter selection and
alternative splicing of p53 still needs to be elucidated.
The p53 regulators MDM2 (and its human analog HDM2)
and MDMX (and its human analog HDMX) also undergo
alternative splicing. Binding of MDM2 to p53 inhibits its
transcriptional function and also facilitates its degradation by
the proteasome. MDMX (also named MDM4) heterodimerizes
with MDM2, affecting MDM2 activity. More than 40
MDM2/HDM2 transcripts, including alternatively as well as
aberrantly spliced forms, have been identified both in tumors
and normal tissue. Some of these variants encode proteins that
possess transforming properties in vitro and in vivo (Bartel et
al., 2002; Lukas et al., 2001). Genomic mutations that can
account for the observed usage of cryptic splice sites and the
generation of aberrantly spliced isoforms have not been found
(Lukas et al., 2001). Moreover, an aberrantly spliced and
tumor-specific HDMX isoform has been recently described.
This transcript, isolated from a thyroid tumor cell line, encodes
a protein named HDMX211, which enhances MDM2 protein
levels and counteracts its p53-degrading function (Giglio et al.,
2005).
Signal transduction, splicing and cancer
Ras pathways
Activation of a pathway involving Ras, PI 3-kinase (PI 3-
kinase) and AKT (the Ras/PI 3-kinase/AKT pathway) has been
associated with multiple human cancers (Bos, 1989; Scheid
and Woodgett, 2001; Vivanco and Sawyers, 2002). This
pathway is counterbalanced by the tumor suppressor
phosphatase PTEN, which in turn is often inactivated in cancer
(Di Cristofano and Pandolfi, 2000). The Ras/PI 3-kinase/AKT
pathway leads to changes in activity of SR proteins, in
particular SF2/ASF and 9G8. Consequently, it regulates
alternative splicing of fibronectin transcripts. Furthermore,
AKT can phosphorylate SF2/ASF and 9G8 in vitro (Blaustein
et al., 2004; Blaustein et al., 2005). Activation of this pathway
by insulin regulates the activity of another SR protein, SRp40,
stimulating the inclusion of an alternative exon in protein
kinase C (PKC)II pre-mRNA (Patel et al., 2001; Patel et al.,
2005). It is tempting to speculate that deregulation of the Ras/
PI 3-kinase/AKT pathway by activating mutations in its
components or by PTEN inactivation would have dramatic
consequences for the splicing pattern of any of the pre-mRNAs
regulated by these splicing factors.
Several reports implicate other Ras-dependent pathways in
the regulation of alternative splicing of the genes encoding
agrin, CD44 and CD45 (Konig et al., 1998; Lynch and Weiss,
2000; Smith et al., 1997; Weg-Remers et al., 2001; Weg-
Remers et al., 2002). CD44 is one of the most studied
alternatively spliced genes in cancer because inclusion of
variable exons correlates with tumor development and
metastasis (Brinkman, 2004; Stickeler et al., 1999; Venables,
2004). In T-lymphoma cells, phorbol-ester-dependent
activation of extracellular-signal-regulated kinase (ERK) leads
to phosphorylation of the nuclear RNA-binding protein Sam68,
which regulates alternative splicing of variable exon 5 in CD44
(Matter et al., 2002). Cheng and Sharp recently identified
SRm160 as another Ras-regulated splicing co-activator
responsible for inclusion of this exon in CD44 (Cheng and
Sharp, 2006). Furthermore, they demonstrated that silencing of
this factor decreases cell invasiveness, providing another link
between regulation of alternative splicing and tumorigenesis.
Several questions remain to be answered. First, whether
changes in the splicing patterns of different genes involved in
neoplastic transformation result from the deregulation of a
certain set of splicing factors. Second, whether a given
extracellular signal can affect different alternative splicing
events that cooperatively participate in tumor progression.
Signaling to the splicing machinery
It is becoming increasingly clear that alternative splicing is
regulated by extracellular signals through the activation of
complex networks of transduction pathways (Lynch, 2004;
Pelisch et al., 2005; Shin and Manley, 2004). However, data
addressing how these extracellular signals impinge upon
splicing factor activity are scarce (Allemand et al., 2005;
Blaustein et al., 2005; Matter et al., 2002; Patel et al., 2005;
van der Houven van Oordt et al., 2000; Xie et al., 2003). Serine












is an important modulator of SR protein activity and
localization. Protein kinases that phosphorylate SR proteins
and their antagonistic hnRNP proteins could play a crucial role
in linking extracellular cues to regulation of alternative
splicing. A recent study (Ngo et al., 2005) supports a model in
which SF2/ASF is first phosphorylated in the cytoplasm by SR-
protein-specific kinase 1 (SRPK1) on only a few serine
residues within the RS domain. This hypophosphorylated
SF2/ASF is imported into the nucleus and stored in nuclear
speckles. Release of SF2/ASF from these storage sites and its
recruitment to active sites of transcription requires a second
round of phosphorylation, which is carried out by CDC-like
kinase 1 (CLK). Dephosphorylation of SF2/ASF is required for
its activity during mRNA splicing, and so it is conceivable
that it must undergo dephosphorylation by as-yet-unknown
phosphatases (Huang et al., 2004).
Although SRPK and CLK have been identified as SR protein
kinases, signaling pathways that involve these kinases have not
been identified. As already mentioned, AKT can also
phosphorylate SR proteins, in particular SF2/ASF, 9G8 and
SRp40. ERK phosphorylates the RNA-binding protein Sam68,
which is involved in the regulation of CD44 alternative splicing
(Matter et al., 2002). ERK-dependent activation of Sam68
triggers the formation of a macromolecular complex that
contains Sam68, Pol II and Brm (a component of the SWI/SNF
chromatin-remodeling complex). This interacts with the nascent
transcript, stalling Pol II (Batsche et al., 2006). Such pausing
could favor inclusion of the variable exons within the mature
mRNA, which would be consistent with the proposed kinetic
coupling between transcription and splicing (Kornblihtt, 2006).
The balance of different kinase activities could modulate the
function of splicing regulatory proteins and consequently
modify splicing patterns. But there are still more questions than
answers. What is the SR protein specificity, if any, of all these
kinases? Is there a precise order in which each phosphorylation
takes place? Which residues are involved in each case? Does
each kinase affect different SR protein properties (e.g. RNA
binding, protein-protein interaction, or protein localization) or
functions (e.g. splicing, surveillance, or translation) (Huang
and Steitz, 2005)?
Conclusion and perspectives
Cancer is a multistep process that involves severe changes in
gene expression. The more we learn about regulatory pathways
that are disturbed during tumorigenesis, the more we realize
about the complexity of tissue homeostasis.
Mutations that alter cis-acting splicing elements can modify
mRNA quality and therefore protein function. Activation of
signaling pathways that can affect the activity of splicing
regulatory factors or modify the balance between them can also
change the proportions of mRNA splicing isoforms. Both can
lead to the deregulation of crucial cellular processes such as
adhesion, proliferation, differentiation, death, motility and
invasion (Fig. 3), all of which contribute to cancer.
Although still in development, splice-isoform-sensitive
microarrays will undoubtedly contribute towards the analysis
of changes in splicing patterns associated with cancer (Li et al.,
2006; Relogio et al., 2005). Establishing which genes actively
participate in different steps of tumor initiation and
progression, or whether deregulation of their splicing is a
consequence of this, will require both high-throughput
techniques and reductionist approaches in culture and animal
models.
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